MedTrace Logo

Xarelto on Prevention of Stroke and Non-Central Nervous Systemic Embolism in Renally Impaired Korean Patients With Non-valvular Atrial Fibrillation

NCT03746301 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 924

Last updated 2022-12-08

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety and effectiveness of Xarelto in renally impaired patients with NVAF under routine practice conditions. The information collected in the XARENAL study will help to understand how renally impared patients with NVAF are treated in the real-world setting and what the outcome for the patients is under those conditions.

Conditions

  • Non-valvular Atrial Fibrillation (NVAF)

Interventions

DRUG

Rivaroxaban(Xarelto,BAY 59-7939)

10mg, 15mg and 20 mg film-coated tablets

Sponsors & Collaborators

  • Janssen Research & Development, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-03
Primary Completion
2021-07-28
Completion
2021-12-15

Countries

  • South Korea

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03746301 on ClinicalTrials.gov